Authors

Latest:

Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLC

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

Alexander J. Lazar, MD, PhD

Latest:

Dr. Lazar on the Current State of Diagnosis and Treatment in Desmoid Tumors

Alexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.

Karine Tawagi, MD

Latest:

Board Review Resources 2024

Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.

Jason Romancik, MD

Latest:

Dr. Romancik on Maximizing CAR T-cell Therapy in NHL

Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.

Julia Blanter, MD

Latest:

Dr. Blanter on Racial Disparities in Development of Distant Metastases in Breast Cancer

Julia Blanter, MD, discusses the risk of developing distant metastases after initial breast cancer diagnosis among Black vs White women.

Naseema Gangat, MD

Latest:

Dr Gangat on JAK Inhibitor Selection in Treatment-Naive Myelofibrosis

Naseema Gangat, MBBS discusses the clinical utility of momelotinib and JAK inhibitor selection in treatment-naive myelofibrosis.

Shruti Tiwari, MD

Latest:

Dr Tiwari on the Current Treatment Paradigms for HER2-Positive and HER2-Low Breast Cancers

Shruti Tiwari, MD, discusses how the treatment paradigms for HER2-positive and HER2-low breast cancer has evolved in recent years.

Candice Schwartz, MD

Latest:

Biomarkers Drive ICIs in Colon Cancer

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.

Washington University School of Medicine in St. Louis

Latest:

Siteman Cancer Center Names New Deputy Director Among Other Leadership Appointments

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.

Dietmar Berger, Global Head of Development, Sanofi

Latest:

Advancing Care in Metastatic Breast Cancer

Sponsored Content by SANOFI

Danielle K. DePalo, MD

Latest:

Dr DePalo on First-Line Therapies in Unresectable Melanoma In-Transit Metastases

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

Steven Maron, MD, MSS

Latest:

Dr. Maron on the Role of PD-1 Inhibition in Esophagogastric Cancer

Steven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.

Vilde D. Haakensen, MD, PhD

Latest:

Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLC

Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.

Benjiman Saylor

Latest:

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

UCLA Health Jonsson Comprehensive Cancer Center

Latest:

UCLA Study Finds Combination Therapy Suppresses Pancreatic Tumor Growth in Mice

UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling

Suzanne Trudel, MSc, MD

Latest:

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple Myeloma

Suzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.

Peter Forsyth, MD

Latest:

Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

UC Davis Health

Latest:

New California Tobacco Cessation Policy Research Center to be Housed at Cancer Center

UC Davis Comprehensive Cancer Center has launched the state’s first-ever Tobacco Cessation Policy Research Center.

Yael Cohen, MD

Latest:

Dr Cohen on Teclistamab Plus Talquetamab in R/R Multiple Myeloma

Yael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Cameron James Oswalt MD

Latest:

Dr Oswalt on the Effects of Palliative Care Timing on End-of-Life Care in mNSCLC

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.